Also, the FDA in 2021 approved the combined treatment of tiragulumab with atezolizumab as the first-line treatment for patients with non-small cell lung cancer (NSCLC) malignancy and tumor cells with high expression of PD-L1 without mutations in the tumor gene EGFR (126). This evidence concerns the gene EGFR and non-small cell lung carcinoma.